Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?. [Review]
Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?. [Review]
- 2019
PURPOSE OF REVIEW: Identification of targetable mutations such as EGFR has allowed opportunity for Tyrosine Kinase Inhibitor (TKI) therapy for lung cancer treatment. EGFR-TKIs have revolutionized treatment of advanced EGFR mutant Non-Small Cell Lung Cancer (NSCLC), but there is little evidence that EGFR-TKI treatment is effective in stage III NSCLC. Here we discuss recent evidence supporting the use of EGFR-TKI therapy in combination with chemotherapy and radiation in stage III NSCLC. RECENT FINDINGS: Recent results of small trials testing EGFR-TKI therapy in combination with chemoradiation showed promising efficacy, improved outcomes, and a tolerable toxicity profile when administered to patients with EGFR mutant stage III NSCLC. However, strong supporting evidence regarding EGFR-TKI therapy in stage III NSCLC is lacking because previous trials involved a small patient population or were terminated due to slow participant accrual. Despite the lack of large randomized clinical trials, results from early-stage trials highlight promising future directions for investigating the use of EGFR-TKI therapy in stage III NSCLC treatment.
English
1523-3790
10.1007/s11912-019-0835-x [doi] 10.1007/s11912-019-0835-x [pii]
*Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy]
*Lung Neoplasms/dt [Drug Therapy]
*Protein Kinase Inhibitors/tu [Therapeutic Use]
Antineoplastic Agents/pd [Pharmacology]
Antineoplastic Agents/tu [Therapeutic Use]
Carcinoma, Non-Small-Cell Lung/en [Enzymology]
Carcinoma, Non-Small-Cell Lung/ge [Genetics]
Carcinoma, Non-Small-Cell Lung/pa [Pathology]
Clinical Trials as Topic
ErbB Receptors/ai [Antagonists & Inhibitors]
ErbB Receptors/ge [Genetics]
Humans
Lung Neoplasms/en [Enzymology]
Lung Neoplasms/ge [Genetics]
Lung Neoplasms/pa [Pathology]
Molecular Targeted Therapy/mt [Methods]
Mutation
Neoplasm Staging
Protein Kinase Inhibitors/pd [Pharmacology]
Randomized Controlled Trials as Topic
Washington Cancer Institute
Journal Article
Review
PURPOSE OF REVIEW: Identification of targetable mutations such as EGFR has allowed opportunity for Tyrosine Kinase Inhibitor (TKI) therapy for lung cancer treatment. EGFR-TKIs have revolutionized treatment of advanced EGFR mutant Non-Small Cell Lung Cancer (NSCLC), but there is little evidence that EGFR-TKI treatment is effective in stage III NSCLC. Here we discuss recent evidence supporting the use of EGFR-TKI therapy in combination with chemotherapy and radiation in stage III NSCLC. RECENT FINDINGS: Recent results of small trials testing EGFR-TKI therapy in combination with chemoradiation showed promising efficacy, improved outcomes, and a tolerable toxicity profile when administered to patients with EGFR mutant stage III NSCLC. However, strong supporting evidence regarding EGFR-TKI therapy in stage III NSCLC is lacking because previous trials involved a small patient population or were terminated due to slow participant accrual. Despite the lack of large randomized clinical trials, results from early-stage trials highlight promising future directions for investigating the use of EGFR-TKI therapy in stage III NSCLC treatment.
English
1523-3790
10.1007/s11912-019-0835-x [doi] 10.1007/s11912-019-0835-x [pii]
*Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy]
*Lung Neoplasms/dt [Drug Therapy]
*Protein Kinase Inhibitors/tu [Therapeutic Use]
Antineoplastic Agents/pd [Pharmacology]
Antineoplastic Agents/tu [Therapeutic Use]
Carcinoma, Non-Small-Cell Lung/en [Enzymology]
Carcinoma, Non-Small-Cell Lung/ge [Genetics]
Carcinoma, Non-Small-Cell Lung/pa [Pathology]
Clinical Trials as Topic
ErbB Receptors/ai [Antagonists & Inhibitors]
ErbB Receptors/ge [Genetics]
Humans
Lung Neoplasms/en [Enzymology]
Lung Neoplasms/ge [Genetics]
Lung Neoplasms/pa [Pathology]
Molecular Targeted Therapy/mt [Methods]
Mutation
Neoplasm Staging
Protein Kinase Inhibitors/pd [Pharmacology]
Randomized Controlled Trials as Topic
Washington Cancer Institute
Journal Article
Review